Author

James Izanec 1

1 Janssen Scientific Affairs, LLC,Horsham,United States

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Christopher Gasink, Edward V. Loftus Jr, Timothy Hoops, James Izanec, Tony Ma, Zhijie Ding, Erik Muser, Peter Irving, Matthieu Allez, William J. Sandborn, Remo Panaccione, Silvio Danese

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Matthieu Allez, James D. Lewis, Peter Irving, Timothy Hoops, James Izanec, Tony Ma, Zhijie Ding, Erik Muser, Christopher Gasink, Remo Panaccione, Edward V. Loftus Jr, Bruce E. Sands, Silvio Danese

Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

Steve Hanauer, Bruce E. Sands, Brian G. Feagan, A Oortwijn, Roger van Kruchten, Victor Laliman, James Izanec, Joseph Adedokun, Long-Long Gao, Sheldon Sloan, Christopher Gasink, S Targan, Willem de Villiers, Paul Rutgeerts, Jean-Frédéric Colombel, Subrata Ghosh

THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY

Silvio Danese, James Izanec, Tony Ma, Omoniyi J. Adedokun, Christopher Gasink, Stephen B Hanauer, Ellen Scherl, Kamal Patel

Item 1 - 4 / 4
1